Nanobiotix S.A.
- NBTX
- NASDAQ
- Biotechnology
- Nanoparticle Oncology
- Radiotherapy Enhancer
- Cancer Therapy
$21.08
Today −1.03%Quote Oct 19, 2026, 08:00 PM UTC
−36.22%over the last month
Max drawdown −40.2%From 1-month high −40.2%3 months −46.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Nanobiotix
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles.
Where the money comes from
Q2 2021 revenue $1.3M
- Other Sales$5,0000.4%
- Services$5,0000.4%
- Other / not reported$1.3M99.2%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
97
Founded
2003
Market value
$1.07B
Quote Oct 19
Floor
$20.36
3.4% below price
Resistance
$22.15
5.1% above price
Price vs analyst targets
4 analysts
Lowest target
$30.00Highest target
$46.00
$30.00Highest target
$46.00
- Price $21.08
- Average target $38.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 80% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about NBTXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free